Donate

industry-news

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here.

CSL Behring today presented data from a Phase III pivotal study of Afstyla [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla. The results showed that Afstyla, used prophylactically across different treatment intervals (including two to three times weekly), achieved low annualized spontaneous bleeding rates and low annualized bleeding rates in previously treated children and adolescents with hemophilia A.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.